论文部分内容阅读
目的用动态血糖监测方法评价糖脉康颗粒联合门冬胰岛素30注射液治疗2型糖尿病时对患者血糖漂移及低血糖发生率的影响。方法选取64例2型糖尿病患者,随机分为观察组和对照组,各32例。两组均给予2次/d门冬胰岛素30注射液皮下注射,观察组另联合糖脉康颗粒3次/d口服。采用动态血糖监测的方法,评价两组患者血糖漂移幅度、日胰岛素用量及低血糖发生情况。结果血糖达标持续3个月后,观察组患者的日均胰岛素用量〔(28.6±7.4)U/d〕、日内血糖最高值〔(13.1±1.2)mmol/L〕、平均血糖漂移幅度〔(7.4±1.2)mmol/L〕均显著低于对照组〔分别为(35.4±5.2)U/d、(16.2±1.6)mmol/L、(8.4±1.7)mmol/L〕,差异有统计学意义(P<0.05);另外,观察组患者发生低血糖7人次(5例),对照组5人次(4例),两组患者低血糖发生率(15.6%与12.5%)比较,差异无统计学意义(P>0.05)。结论在血糖控制达标时,与单用门冬胰岛素30注射液比较,糖脉康颗粒联合门冬胰岛素30注射液治疗能降低2型糖尿病患者的血糖漂移幅度及日均胰岛素用量,且不增加低血糖发生率。
Objective To evaluate the effect of Tangmikang granule combined with insulin aspart 30 injection on blood sugar drift and incidence of hypoglycemia in patients with type 2 diabetes mellitus with dynamic glucose monitoring. Methods Sixty-four patients with type 2 diabetes mellitus were randomly divided into observation group and control group, with 32 cases in each group. Both groups were given 2 times / d aspart insulin 30 injection subcutaneously, the observation group combined with Tangmai Kang particles 3 times / d orally. The method of dynamic blood glucose monitoring was used to evaluate the extent of blood glucose drifts, the daily insulin dosage, and the incidence of hypoglycaemia in both groups. Results After the blood glucose reached the standard for 3 months, the average daily insulin dose (28.6 ± 7.4) U / d in the observation group, the highest intra-day blood glucose 〔(13.1 ± 1.2) mmol / L〕, the average blood glucose drift 〔(7.4 ± 1.2) mmol / L] were significantly lower than those in the control group [(35.4 ± 5.2) U / d, (16.2 ± 1.6) mmol / L and (8.4 ± 1.7) mmol / L, respectively] P <0.05). In addition, there were 7 hypoglycemia patients (5 patients) and 5 patients (4 patients) in the observation group. There was no significant difference in the incidence of hypoglycemia between the two groups (15.6% vs 12.5%) (P> 0.05). Conclusion When glycemic control is reached, compared with aspart insulin 30 injection alone, treatment with Tangmaikang granule combined with insulin aspart 30 can reduce blood glucose level and daily insulin dosage in patients with type 2 diabetes without increasing low Blood sugar incidence.